Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade

References

• Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 9(1), 16–32 (2012).
   PubMed Web of Science ®Google Scholar
• Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 5(1), 5–23 (2011).
   PubMed Web of Science ®Google Scholar
• Caras I, Grigorescu A, Stavaru C et al. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol. Immunother. 53(12), 1146–1152 (2004).
   PubMed Web of Science ®Google Scholar
• Molling JW, Kölgen W, van der Vliet HJ et al. Peripheral blood IFN-γ-secreting Va24+Vb11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int. J. Cancer 116(1), 87–93 (2005).
   PubMed Web of Science ®Google Scholar
• Konjevic G, Radenkovic S, Srdic T, Jurisic V, Stamatovic Lj, Milovic M. Association of decreased NK cell activity and IFN? expression with pSTAT dysregulation in breast cancer patients. J. BUON. 16(2), 219–226 (2011).
   PubMed Web of Science ®Google Scholar
• Gruber IV, El Yousfi S, Dürr-Störzer S, Wallwiener D, Solomayer EF, Fehm T. Down-regulation of CD28, TCR-zeta (z) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Res. 28(2A), 779–784 (2008).
   PubMed Web of Science ®Google Scholar
• Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9(2), 606–612 (2003).
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58(1), 49–59 (2009).
   PubMed Web of Science ®Google Scholar
• Polat MF, Taysi S, Polat S, Böyük A, Bakan E. Elevated serum arginase activity levels in patients with breast cancer. Surg. Today 33(9), 655–661 (2003).
   PubMed Web of Science ®Google Scholar
• Pockaj BA, Basu GD, Pathangey LB et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann. Surg. Oncol. 11(3), 328–339 (2004).
   PubMed Web of Science ®Google Scholar
• Pinzon-Charry A, Ho CS, Maxwell T et al. Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br. J. Cancer 97(9), 1251–1259 (2007).
   PubMed Web of Science ®Google Scholar
• Treilleux I, Blay JY, Bendriss-Vermare N et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 10(22), 7466–7474 (2004).
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Heikkila P, von Smitten K, Vakkila J, Leidenius M. Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8+ T cells. Virchows Arch. 459(4), 391–398 (2011).
   PubMed Web of Science ®Google Scholar
• Ito M, Minamiya Y, Kawai H et al. Tumor-derived TGFb-1 induces dendritic cell apoptosis in the sentinel lymph node. J. Immunol. 176(9), 5637–5643 (2006).
   PubMed Web of Science ®Google Scholar
• Kristensen VN, Vaske CJ, Ursini-Siegel J et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc. Natl Acad. Sci. USA 109(8), 2802–2807 (2012).
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Barreto JB, Andreu P et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16(2), 91–102 (2009).
   PubMed Web of Science ®Google Scholar
• Tan W, Zhang W, Strasner A et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling. Nature 470(7335), 548–553 (2011).
   PubMed Web of Science ®Google Scholar
• Gobbi G, Mirandola P, Micheloni C et al. Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions. Int. J. Oncol. 25(6), 1625–1629 (2004).
   PubMed Web of Science ®Google Scholar
• Herrmann F, Lehr HA, Drexler I et al. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res. 64(1), 215–220 (2004).
   PubMed Web of Science ®Google Scholar
• Baratelli F, Lin Y, Zhu L et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J. Immunol. 175(3), 1483–1490 (2005).
   PubMed Web of Science ®Google Scholar
• Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res. Treat. 50(1), 27–36 (1998).
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Mohammed S, Al-Omair A et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8(3), 190–198 (2006).
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Tulbah A, Mohammed S et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int. J. Cancer 121(4), 751–758 (2007).
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 8, 57 (2008).
   PubMed Web of Science ®Google Scholar
• Crane CA, Panner A, Murray JC et al. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene 28(2), 306–312 (2009).
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Lehe C, Barhoush E et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res. 12(4), R48 (2010).
   Google Scholar
• Tringler B, Zhuo S, Pilkington G et al. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin. Cancer Res. 11(5), 1842–1848 (2005).
   PubMed Web of Science ®Google Scholar
• Salceda S, Tang T, Kmet M et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell Res. 306(1), 128–141 (2005).
   PubMed Web of Science ®Google Scholar
• Sadun RE, Sachsman SM, Chen X et al. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin. Cancer Res. 13(13), 4016–4025 (2007).
   PubMed Web of Science ®Google Scholar
• Mugler KC, Singh M, Tringler B et al. B7-h4 expression in a range of breast pathology: correlation with tumor T-cell infiltration. Appl. Immunohistochem. Mol. Morphol. 15(4), 363–370 (2007).
   PubMedGoogle Scholar
• Fridman WH, Galon J, Pagès F, Tartour E, Sautès-Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 71(17), 5601–5605 (2011).
   PubMed Web of Science ®Google Scholar
• Ladoire S, Arnould L, Apetoh L et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating FOXP3+ regulatory T cells. Clin. Cancer Res. 14(8), 2413–2420 (2008).
   PubMed Web of Science ®Google Scholar
• de Kruijf EM, van Nes JG, Sajet A et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin. Cancer Res. 16(4), 1272–1280 (2010).
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28(1), 105–113 (2010).
   PubMed Web of Science ®Google Scholar
• West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 13(6), R126 (2011).
   PubMed Web of Science ®Google Scholar
• Ladoire S, Mignot G, Dabakuyo S et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J. Pathol. 224(3), 389–400 (2011).
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Paish EC, Powe DG et al. An evaluation of the clinical signficiance of FOXP3+ infiltrating cells in human breast cancer. J ClinOncol. 29(15), 1949–1955 (2011).
   PubMed Web of Science ®Google Scholar
• Martinet L, Garrido I, Filleron T et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 71(17), 5678–5687 (2011).
   PubMed Web of Science ®Google Scholar
• Domschke C, Schuetz F, Ge Y et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res. 69(21), 8420–8428 (2009).
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13(9), 1050–1059 (2007).
   PubMed Web of Science ®Google Scholar
• Demaria S, Volm MD, Shapiro RL et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin. Cancer Res. 7(10), 3025–3030 (2001).
   PubMed Web of Science ®Google Scholar
• Generali D, Bates G, Berruti A et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin. Cancer Res. 15(3), 1046–1051 (2009).
   PubMed Web of Science ®Google Scholar
• Benzaïd I, Mönkkönen H, Stresing V et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vg9Vd2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 71(13), 4562–4572 (2011).
   PubMed Web of Science ®Google Scholar
• Meravigilia S, Eberi M, Vermijien D et al. In vivo manipulation of Vg9Vd2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp. Immunol. 161(2), 290–297 (2010).
   PubMed Web of Science ®Google Scholar
• Taylor C, Hershman D, Shah N et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 13(17), 5133–5143 (2007).
   PubMed Web of Science ®Google Scholar
• Ladoire S, Arnould L, Mignot G et al. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br. J. Cancer 105(3), 366–371 (2011).
   PubMed Web of Science ®Google Scholar
• Walker LS, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2(1), 11–19 (2002).
   PubMed Web of Science ®Google Scholar
• Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160(2), 643–651 (1998).
   PubMed Web of Science ®Google Scholar
• Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 3(4), 407–415 (1995).
   PubMed Web of Science ®Google Scholar
• De Visser KE, Schumacher TN, Kruisbeek AM. CD8+ T cell tolerance and cancer immunotherapy. J. Immunother. 26(1), 1–11 (2003).
   PubMed Web of Science ®Google Scholar
• Lyman MA, Nugent CT, Marquardt KL, Biggs JA, Pamer EG, Sherman LA. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J. Immunol. 174(5), 2563–2572 (2005).
   PubMed Web of Science ®Google Scholar
• Hernández J, Ko A, Sherman LA. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J. Immunol. 166(6), 3908–3914 (2001).
   PubMed Web of Science ®Google Scholar
• Gross DA, Graff-Dubois S, Opolon P et al. High vaccination efficiency of low-affinity epitopes in anti-tumor immunotherapy. J. Clin. Invest. 113(3), 425–433 (2004).
   PubMed Web of Science ®Google Scholar
• Ercolini AM, Ladle BH, Manning EA et al. Recruitment of latent pools of high-avidity CD8+ T cells to the anti-tumor immune response. J. Exp. Med. 201(10), 1591–1602 (2005).
   PubMed Web of Science ®Google Scholar
• Shevach EM. Biological functions of regulatory T cells. Adv. Immunol. 112, 137–176 (2011).
   PubMed Web of Science ®Google Scholar
• Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J. Immunother. 35(2), 107–115 (2012).
   PubMed Web of Science ®Google Scholar
• Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin. Cancer Res. 17(22), 6985–6991 (2011).
   PubMed Web of Science ®Google Scholar
• Munder M. Arginase: an emerging key player in the mammalian immune system. Br. J. Pharmacol. 158(3), 638–651 (2009).
   PubMed Web of Science ®Google Scholar
• Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol. 37(5), 430–439 (2010).
   PubMed Web of Science ®Google Scholar
• Disis ML, Calenoff E, McLaughlin G et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54(1), 16–20 (1994).
   PubMed Web of Science ®Google Scholar
• Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol. 15(11), 3363–3367 (1997).
   PubMed Web of Science ®Google Scholar
• Miles D, Papazisis K. Rationale for the clinical development of STn-KLH (Theratope®) and anti-MUC-1 vaccines in breast cancer. Clin. Breast Cancer 3(Suppl. 4), S134–S138 (2003).
   PubMed Web of Science ®Google Scholar
• Pardoll DM, Topalian SL. The role of CD4+ T cell responses in anti-tumor immunity. Curr. Opin. Immunol. 10(5), 588–594 (1998).
   PubMed Web of Science ®Google Scholar
• Curcio C, Di Carlo E, Clynes R et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J. Clin. Invest. 111(8), 1161–1170 (2003).
   PubMed Web of Science ®Google Scholar
• Spadaro M, Ambrosino E, Iezzi M et al. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin. Cancer Res. 11(5), 1941–1952 (2005).
   PubMed Web of Science ®Google Scholar
• Murray JL, Gillogly ME, Przepiorka D et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 8(11), 3407–3418 (2002).
   PubMed Web of Science ®Google Scholar
• Peoples GE, Holmes JP, Hueman MT et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 14(3), 797–803 (2008).
   PubMed Web of Science ®Google Scholar
• Holmes JP, Gates JD, Benavides LC et al. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 113(7), 1666–1675 (2008).
   PubMed Web of Science ®Google Scholar
• Amin A, Benavides LC, Holmes JP et al. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol. Immunother. 57(12), 1817–1825 (2008).
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Clifton GT, Holmes JP et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 118(10), 2594–2602 (2012).
   PubMed Web of Science ®Google Scholar
• Holmes JP, Clifton GT, Patil R et al. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 117(3), 463–471 (2011).
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer. Surgery 139(3), 407–418 (2006).
   PubMed Web of Science ®Google Scholar
• Hueman MT, Stojadinovic A, Storrer CE et al. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Breast Cancer Res. Treat. 98(1), 17–29 (2006).
   PubMed Web of Science ®Google Scholar
• Hueman MT, Stojadinovic A, Storrer CE et al. Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol. Immunother. 56(2), 135–146 (2007).
   PubMed Web of Science ®Google Scholar
• Patil R, Clifton GT, Holmes JP et al. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a Phase I/II clinical trial. J. Am. Coll. Surg. 210(2), 140–147 (2010).
   PubMed Web of Science ®Google Scholar
• Benavides LC, Gates JD, Carmichael MG et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 15(8), 2895–2904 (2009).
   PubMed Web of Science ®Google Scholar
• Carmichael MG, Benavides LC, Holmes JP et al. Results of the first Phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 116(2), 292–301 (2010).
   PubMed Web of Science ®Google Scholar
• Holmes JP, Benavides LC, Gates JD et al. Results of the first Phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J. Clin. Oncol. 26(20), 3426–3433 (2008).
   PubMed Web of Science ®Google Scholar
• Gates JD, Clifton GT, Benavides LC et al. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide. Vaccine 28(47), 7476–7482 (2010).
   PubMed Web of Science ®Google Scholar
• Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5(6), 1289–1297 (1999).
   PubMed Web of Science ®Google Scholar
• Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107(4), 477–484 (2001).
   PubMed Web of Science ®Google Scholar
• Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 6(4), 1347–1350 (2000).
   PubMed Web of Science ®Google Scholar
• Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin. Cancer Res. 8(5), 1014–1018 (2002).
   PubMed Web of Science ®Google Scholar
• Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20(11), 2624–2632 (2002).
   PubMed Web of Science ®Google Scholar
• Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J. Clin. Immunol. 24(5), 571–578 (2004).
   PubMed Web of Science ®Google Scholar
• Disis ML, Schiffman K, Guthrie K et al. Effect of dose on immune response in patients vaccinated with an Her-2/neu intracellular domain protein–based vaccine. J. Clin. Oncol. 22(10), 1916–1925 (2004).
   PubMed Web of Science ®Google Scholar
• Czerniecki BJ, Koski GK, Koldovsky U et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 67(4), 1842–1852 (2007).
   PubMed Web of Science ®Google Scholar
• Koski GK, Koldovsky U, Xu S et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J. Immunother. 35(1), 54–65 (2012).
   PubMed Web of Science ®Google Scholar
• Gilewski T, Adluri S, Ragupathi G et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 6(5), 1693–1701 (2000).
   PubMed Web of Science ®Google Scholar
• Gilewski T, Ragupathi G, Bhuta S et al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a Phase I trial. Proc. Natl Acad. Sci. USA 98(6), 3270–3275 (2001).
   PubMed Web of Science ®Google Scholar
• Gilewski TA, Ragupathi G, Dickler M et al. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin. Cancer Res. 13(10), 2977–2985 (2007).
   PubMed Web of Science ®Google Scholar
• Adluri S, Gilewski T, Zhang S, Ramnath V, Ragupathi G, Livingston P. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. Br J Cancer. 79(11–12), 1806–1812 (1999).
   PubMed Web of Science ®Google Scholar
• Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int. J. Cancer 93(1), 97–106 (2001).
   PubMed Web of Science ®Google Scholar
• Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y, Livingston PO. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int. J. Cancer 97(5), 660–667 (2002).
   PubMed Web of Science ®Google Scholar
• Miles DW, Towlson KE, Graham R et al. A randomised Phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer 74(8), 1292–1296 (1996).
   PubMed Web of Science ®Google Scholar
• Miles D, Roché H, Martin M et al.; Theratope® Study Group. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16(8), 1092–1100 (2011).
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252–264 (2012).
   PubMed Web of Science ®Google Scholar
• Garber K. Beyond ipilimumab: new approaches target the immunological synapse. J. Natl. Cancer Inst. 103(14), 1079–1082 (2011).
   PubMedGoogle Scholar
• Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517–2526 (2011).
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167–3175 (2010).
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012).
   PubMed Web of Science ®Google Scholar
• Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Science gone translational: the OX40 agonist story. Immunol. Rev. 244(1), 218–231 (2011).
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, LoRusso PM, Khalil M et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 16(13), 3485–3494 (2010).
   PubMed Web of Science ®Google Scholar
• Brignone C, Gutierrez M, Mefti F et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and anti-tumor activity. J. Transl. Med. 8, 71 (2010).
   PubMed Web of Science ®Google Scholar
• Emens LA. Roadmap to a better therapeutic tumor vaccine. Int Rev Immunol. 25(5–6), 415–443 (2006).
   PubMed Web of Science ®Google Scholar
• Emens LA. Chemotherapy and tumor immunity: an unexpected collaboration. Front. Biosci. 13, 249–257 (2008).
   PubMed Web of Science ®Google Scholar
• Emens LA. Chemoimmunotherapy. Cancer J. 16(4), 295–303 (2010).
   PubMed Web of Science ®Google Scholar
• Emens LA, Silverstein SC, Khleif S, Marincola FM, Galon J. Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J. Transl. Med. 10, 70 (2012).
   PubMed Web of Science ®Google Scholar
• Disis ML, Wallace DR, Gooley TA et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J. Clin. Oncol. 27(28), 4685–4692 (2009).
   PubMed Web of Science ®Google Scholar
• Hamilton E, Blackwell K, Hobeika AC et al. Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion. J. Transl. Med. 10, 28 (2012).
   PubMed Web of Science ®Google Scholar
• Emens LA, Asquith JM, Leatherman JM et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J. Clin. Oncol. 27(35), 5911–5918 (2009).
   PubMed Web of Science ®Google Scholar
• Emens LA, Gupta R, Petrik S et al. A feasibility study of combination therapy with trastuzumab (T), cyclophoshamide (CY) and an allogenic GM-CSF-secreting breast tumor vaccine for the treatment of HER-2+ breast cancer. Proc Am Soc. Clin. Oncol. Abstract 2435 (2011).
   Google Scholar
• Taube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4(127), 127ra37 (2012).
   PubMed Web of Science ®Google Scholar
• Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a Phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J. Clin. Oncol. 25(24), 3680–3687 (2007).
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika A, Osada T et al. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J. Transl. Med. 5, 42 (2007).
   PubMed Web of Science ®Google Scholar
• Wiedermann U, Wiltschke C, Jasinska J et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a Phase I study. Breast Cancer Res. Treat. 119(3), 673–683 (2010).
   PubMed Web of Science ®Google Scholar
• Carr A, Rodríguez E, Arango Mdel C et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J. Clin. Oncol. 21(6), 1015–1021 (2003).
   PubMed Web of Science ®Google Scholar
• Mulens V, de la Torre A, Marinello P et al. Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients. Hum. Vaccin. 6(9), (2010).
   PubMedGoogle Scholar
• Mohebtash M, Tsang KY, Madan RA et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 17(22), 7164–7173 (2011).
   PubMed Web of Science ®Google Scholar
• Domchek SM, Recio A, Mick R et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res. 67(21), 10546–10555 (2007).
   PubMed Web of Science ®Google Scholar
• Svane IM, Pedersen AE, Johnsen HE et al. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a Phase I study. Cancer Immunol. Immunother. 53(7), 633–641 (2004).
   PubMed Web of Science ®Google Scholar
• Svane IM, Pedersen AE, Johansen JS et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol. Immunother. 56(9), 1485–1499 (2007).
   PubMed Web of Science ®Google Scholar
• Dols A, Meijer SL, Hu HM et al. Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J. Immunother. 26(2), 163–170 (2003).
   PubMed Web of Science ®Google Scholar
• Dols A, Smith JW 2nd, Meijer SL et al. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum. Gene Ther. 14(11), 1117–1123 (2003).
   PubMed Web of Science ®Google Scholar
• Avigan D, Vasir B, Gong J et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10(14), 4699–4708 (2004).
   PubMed Web of Science ®Google Scholar
• Tsuruma T, Iwayama Y, Ohmura T et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in Phase I clinical study for patients with advanced or recurrent breast cancer. J. Transl. Med. 6, 24 (2008).
   PubMed Web of Science ®Google Scholar
• Norell H, Poschke I, Charo J et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J. Transl. Med. 8, 53 (2010).
   PubMed Web of Science ®Google Scholar